drugset / Trial / NCT07268820

Heartburn, Gastroesophageal Reflux Disease

NCT07268820

Phase 4 Recruiting 160 enrolled Incheon St.Mary's Hospital
RandomizedParallel-groupDouble-blindOther

Summary

Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation. GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life. This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).

Timeline

Start
2025-07-07
Primary completion
2026-05-29
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 40 mg Oral
Subject Zastaprazan Unknown 20 mg Oral